Applicability of Routine Targeted Next-generation Sequencing to Estimate Tumor Mutational Burden (TMB) in Patients Treated With Immune Checkpoint Inhibitor Therapy

被引：2

作者：

Pinato, David J. ^{[1
,2
]}

Urus, Heather ^{[1
,2
]}

Newsom-Davis, Thomas ^{[3
]}

Du Parcq, Persephone ^{[4
]}

Belessiotis, Katherine ^{[2
]}

Mapara, Leah ^{[2
]}

Gupta, Nandita ^{[5
]}

Power, Danielle ^{[2
]}

Weir, Justin ^{[5
]}

Wong, Ching Ngar ^{[1
]}

Ratnakumaran, Ragu P. ^{[2
]}

Dominy, Kathy ^{[4
]}

Khorashad, Jamshid ^{[4
]}

Bower, Mark ^{[3
]}

机构：

[1] Imperial Coll London, Dept Surg & Canc, London, England

[2] Imperial Coll NHS Trust, Charing Cross Hosp, Dept Oncol, London, England

[3] Chelsea & Westminster Hosp, Dept Oncol, London, England

[4] Hammersmith Hosp, Mol Pathol Lab, London, England

[5] Imperial Coll NHS Trust, Hammersmith Hosp, Dept Histopathol, London, England

来源：

JOURNAL OF IMMUNOTHERAPY | 2020年 / 43卷 / 02期

基金：

英国惠康基金;

关键词：

TMB; immunotherapy; targeted; NGS; panel;

D O I：

10.1097/CJI.0000000000000295

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

It remains unclear whether targeted next-generation sequencing (tNGS) conveys a reliable estimate of tumor mutational burden (TMB). We sequenced 79 archival samples of immune checkpoint inhibitors (ICPIs) recipients (57% lung cancer, 43% melanoma) using Ion Ampliseq Cancer Hotspot Panel. Employing multiple cutoff values, we verified that TMB by tNGS did not correlate with response or survival following ICPI. We found enrichment of ATM mutations in ICPI-refractory tumors (P=0.01) to correlate with worse survival (4.2 vs. 10 mo, P=0.03). Limited-coverage tNGS delivers an imprecise estimate of patients' TMB but may aid identification of candidate somatic variants of predictive/prognostic significance.

引用

页码：53 / 56

页数：4

共 18 条

[1] Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer
Ricciuti, Biagio
Kravets, Sasha
Dahlberg, Suzanne E.
Umeton, Renato
Albayrak, Adem
Subegdjo, Safiya J.
Johnson, Bruce E.
Nishino, Mizuki
Sholl, Lynette M.
Awad, Mark M.
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[2] Qualification of tumour mutational burden by targeted next-generation sequencing as a biomarker in hepatocellular carcinoma
Wong, Ching Ngar
Fessas, Petros
Dominy, Kathy
Mauri, Francesco A.
Kaneko, Takahiro
Parcq, Persephone Du
Khorashad, Jamshid
Toniutto, Pierluigi
Goldin, Robert D.
Avellini, Claudio
Pinato, David J.
LIVER INTERNATIONAL, 2021, 41 (01) : 192 - 203
[3] Predictive value of tumor mutation burden (TMB) with targeted next-generation sequencing in immuno-checkpoint inhibitors for non-small cell lung cancer (NSCLC)
Ma, Xiaoting
Zhang, Yujian
Wang, Shan
Yu, Jing
JOURNAL OF CANCER, 2021, 12 (02): : 584 - 594
[4] Pan-cancer Analysis of Tumor Mutational Burden and Homologous Recombination DNA Damage Repair Using Targeted Next-Generation Sequencing
Wang, Hai-Yun
Deng, Ling
Li, Ying-Qing
Zhang, Xiao
Long, Ya-Kang
Zhang, Xu
Feng, Yan-Fen
He, Yuan
Tang, Tao
Yang, Xin-Hua
Wang, Fang
CANCER RESEARCH AND TREATMENT, 2021, 53 (04): : 973 - 982
[5] Mutational Landscape in Lung Cancer Patients by Targeted Next-Generation Sequencing and Differences by Gender in Spanish Population
Jimenez Munarriz, B.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1043 - S1043
[6] High tumor mutational burden assessed through next-generation sequencing predicts favorable survival in microsatellite stable metastatic colon cancer patients
Di Mauro, Annabella
Santorsola, Mariachiara
Savarese, Giovanni
Sirica, Roberto
Ianniello, Monica
Cossu, Alessia Maria
Ceccarelli, Anna
Sabbatino, Francesco
Bocchetti, Marco
Carratu, Anna Chiara
Pentimalli, Francesca
Ferrara, Gerardo
Nasti, Guglielmo
Caraglia, Michele
Ottaiano, Alessandro
JOURNAL OF TRANSLATIONAL MEDICINE, 2024, 22 (01)
[7] Interplay between Tumor Mutational Burden and Mutational Profile and Its Effect on Overall Survival: A Pilot Study of Metastatic Patients Treated with Immune Checkpoint Inhibitors
Xavier, Camila B.
Lopes, Carlos Diego H.
Awni, Beatriz M.
Campos, Eduardo F.
Alves, Joao Pedro B.
Camargo, Anamaria A.
Guardia, Gabriela D. A.
Galante, Pedro A. F.
Jardim, Denis L.
CANCERS, 2022, 14 (21)
[8] Blood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancers
Barnett, Reagan M.
Jang, Albert
Lanka, Sree
Fu, Pingfu
Bucheit, Leslie A.
Babiker, Hani
Bryce, Alan
Meyer, Haley M.
Choi, Yujin
Moore, Casey
Garje, Rohan
Gao, Xin
Kim, Dae Won
Chang, Richard Y.
Gulhati, Pat
Ramaker, Ryne
Bansal, Rani
Zhang, Tian
Oliver Sartor, A.
Armstrong, Andrew J.
Bilen, Mehmet A.
Barata, Pedro
COMMUNICATIONS MEDICINE, 2024, 4 (01):
[9] Next-Generation Sequencing-Directed Therapy in Patients with Metastatic Breast Cancer in Routine Clinical Practice
Bruzas, Simona
Kuemmel, Sherko
Harrach, Hakima
Breit, Elisabeth
Ataseven, Beyhan
Traut, Alexander
Rueland, Anna
Kostara, Athina
Chiari, Ouafaa
Dittmer-Grabowski, Christine
Reinisch, Mattea
CANCERS, 2021, 13 (18)
[10] Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Inhibitor
Bakaloudi, Dimitra Rafailia
Talukder, Rafee
Makrakis, Dimitrios
Diamantopoulos, Leonidas
Enright, Thomas
Leary, Jacob B.
Patgunarajah, Ubenthira
Thomas, Vinay M.
Swami, Umang
Agarwal, Neeraj
Jindal, Tanya
Koshkin, Vadim S.
Brown, Jason R.
Barata, Pedro
Murgic, Jure
Miletic, Marija
Johnson, Jeffrey
Zakharia, Yousef
Hui, Gavin
Drakaki, Alexandra
Duran, Ignacio
Buznego, Lucia A.
Barrera, Rafael M.
Castaneda, David M.
Rey-Cardenas, Macarena
Castellano, Daniel
Nguyen, Charles B.
Park, Joseph J.
Alva, Ajjai
McKay, Rana R.
Stewart, Tyler F.
Epstein, Ilana B.
Bellmunt, Joaquim
Wright, Jonathan L.
Gupta, Shilpa
Grivas, Petros
Khaki, Ali Raza
CLINICAL GENITOURINARY CANCER, 2024, 22 (06)

← 1 2 →